Alnylam Pharmaceuticals | ALNY - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Amgen USD 653M 94.99B 2026-09
Arrowhead Research USD 24.56M 716K 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Incyte USD 605K 23K 2026-09
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 300K 2.6M 2026-09
Novartis USD 281M 8M 2025-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.38B 466M 2026-09
Tectonic Therapeutic USD 237.03M 9.54M 2026-06
Ultragenyx Pharmaceutical USD 20M 2M 2026-09
Vertex Pharmaceuticals USD 36M 32.7M 2026-09
Xencor USD 4.11M 3.24M 2026-09